Advanced search    

Search: authors:"Harutsugu Tatebe"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients

: Makiko Shinomoto, Takashi Kasai, Harutsugu Tatebe. Formal analysis: Takashi Kasai, Isao Yokota. Funding acquisition: Takashi Kasai, Takahiko Tokuda. 10 / 13 Investigation: Takashi Kasai, Harutsugu Tatebe

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

There is still a substantial unmet need for less invasive and lower-cost blood-based biomarkers to detect brain Alzheimer’s disease (AD) pathology. This study is aimed to determine whether quantification of plasma tau phosphorylated at threonine 181 (p-tau181) is informative in the diagnosis of AD. We have developed a novel ultrasensitive immunoassay to quantify plasma p-tau181...

Increased levels of plasma total tau in adult Down syndrome

Conceptualization: Takashi Kasai, Masaki Kondo, Masafumi Morimoto, Tomohiro Chiyonobu, Masanori Nakagawa, Takahiko Tokuda. Data curation: Takashi Kasai, Harutsugu Tatebe. Formal analysis: Takashi Kasai. 9 / 12 ... Investigation: Takashi Kasai, Harutsugu Tatebe, Masaki Kondo, Ryotaro Ishii, Takuma Ohmichi, Takahiko Tokuda. Methodology: Takashi Kasai. Project administration: Takashi Kasai. Resources: Takashi Kasai

Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy

The COQ2 gene encodes an essential enzyme for biogenesis, coenzyme Q10 (CoQ10). Recessive mutations in this gene have recently been identified in families with multiple system atrophy (MSA). Moreover, specific heterozygous variants in the COQ2 gene have also been reported to confer susceptibility to sporadic MSA in Japanese cohorts. These findings have suggested the potential...

Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference

There is substantial biochemical, pathological, and genetic evidence that α-synuclein (A-syn) is a principal molecule in the pathogenesis of Parkinson disease (PD). We previously reported that total A-syn levels in cerebrospinal fluid (CSF), measured with the specific enzyme-linked immunosorbent assay (ELISA) developed by ourselves, were decreased in patients with PD, and...

Differential Expression of Alpha-Synuclein in Hippocampal Neurons

α-Synuclein is the major pathological component of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Recent studies have demonstrated that α-synuclein also plays important roles in the release of synaptic vesicles and synaptic membrane recycling in healthy neurons. However, the precise relationship between the pathogenicity and physiological functions...

p62/SQSTM1-Dependent Autophagy of Lewy Body-Like α-Synuclein Inclusions

α-Synuclein is the main component of Lewy bodies, the intraneuronal inclusion bodies characteristic of Parkinson’s disease. Although α-synuclein accumulation is caused by inhibition of proteasome and autophagy-lysosome, the degradation of α-synuclein inclusions is still unknown. Formation of Lewy body-like inclusions can be replicated in cultured cells by introducing α-synuclein...